Skip to Main Content

Paper Details

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Leukemia
8
2023
ABL1 T315I, ABL1 T315I mutations, AOEs, Asciminib, BCR, CML, CML-CP, Philadelphia, T315I, arterial occlusive events, asciminib, chronic-phase chronic myeloid leukemia, fatigue, hypertension, musculoskeletal pain, neutropenia, pancreatitis, patients, thrombocytopenia, tyrosine, tyrosine kinase, upper respiratory tract infection
Author NameAffiliation
Dong Wook KimUijeongbu Eulji Medical Center
Dong Wook KimUijeongbu Eulji Medical Center
Hagop KantarjianUniversity of Michigan Rogel Cancer Center ann arbor
Daniel J DeAngeloDana-Farber Cancer Institute
Michael W DeiningerVersiti Blood Research Institute
  • 1 - 5

Datasets

Release 1.2